ECSP11011470A - Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades - Google Patents
Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedadesInfo
- Publication number
- ECSP11011470A ECSP11011470A EC2011011470A ECSP11011470A ECSP11011470A EC SP11011470 A ECSP11011470 A EC SP11011470A EC 2011011470 A EC2011011470 A EC 2011011470A EC SP11011470 A ECSP11011470 A EC SP11011470A EC SP11011470 A ECSP11011470 A EC SP11011470A
- Authority
- EC
- Ecuador
- Prior art keywords
- cancer
- diseases
- treatment
- pyrimidine
- new derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a compuestos de Fórmula (I); donde L1, R1, R2, R3, R4 y X son como se los define en la descripción. La presente invención también se refiere a procesos para la preparación de dichos compuestos, composiciones farmacéuticas que los contienen y su uso en el tratamiento de enfermedades, por ejemplo, cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18023809P | 2009-05-21 | 2009-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP11011470A true ECSP11011470A (es) | 2011-12-30 |
Family
ID=42315702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2011011470A ECSP11011470A (es) | 2009-05-21 | 2011-11-21 | Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades |
Country Status (23)
Country | Link |
---|---|
US (2) | US20120122867A1 (es) |
EP (1) | EP2432768B1 (es) |
JP (1) | JP5913093B2 (es) |
KR (1) | KR20120030436A (es) |
CN (1) | CN102482233A (es) |
AR (1) | AR078045A1 (es) |
AU (1) | AU2010250923A1 (es) |
BR (1) | BRPI1010937A2 (es) |
CA (1) | CA2760766A1 (es) |
CL (1) | CL2011002942A1 (es) |
CO (1) | CO6470845A2 (es) |
CR (1) | CR20110610A (es) |
CU (1) | CU20110212A7 (es) |
DO (1) | DOP2011000361A (es) |
EA (1) | EA201101650A1 (es) |
EC (1) | ECSP11011470A (es) |
IL (1) | IL216283A0 (es) |
MX (1) | MX2011012337A (es) |
SG (1) | SG175796A1 (es) |
TW (1) | TW201100083A (es) |
UY (1) | UY32648A (es) |
WO (1) | WO2010133885A1 (es) |
ZA (1) | ZA201109384B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2012DN02984A (es) | 2009-10-22 | 2015-07-31 | Gilead Sciences Inc | |
WO2012066336A1 (en) * | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
WO2012066335A1 (en) * | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Phenol compounds als toll -like receptor 7 agonists |
WO2012067268A1 (en) * | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Cyclic amide compounds and their use in the treatment of disease |
WO2012067269A1 (en) * | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Aminoalkoxyphenyl compounds and their use in the treatment of disease |
ES2575688T3 (es) | 2010-12-16 | 2016-06-30 | Sumitomo Dainippon Pharma Co., Ltd. | Derivado de imidazo[4,5-c]quinolin-1-ilo útil en terapia |
JP5978226B2 (ja) | 2010-12-17 | 2016-08-24 | 大日本住友製薬株式会社 | プリン誘導体 |
EP2663367A4 (en) | 2011-01-10 | 2014-08-06 | Cleveland Biolabs Inc | USE OF A TOLL-TYPE RECEPTOR AGONIST FOR THE TREATMENT OF CANCER |
ES2691745T3 (es) * | 2011-04-08 | 2018-11-28 | Janssen Sciences Ireland Uc | Derivados de pirimidina para el tratamiento de infecciones víricas |
RS57851B1 (sr) | 2011-11-09 | 2018-12-31 | Janssen Sciences Ireland Uc | Purinski derivati za tretman viralnih infekcija |
FR2985256B1 (fr) * | 2011-12-30 | 2016-03-04 | Pitty Marc Henry | Derives piperazinyles pour le traitement de cancers |
US9133192B2 (en) * | 2012-02-08 | 2015-09-15 | Janssen Sciences Ireland Uc | Piperidino-pyrimidine derivatives for the treatment of viral infections |
AU2013261267B2 (en) * | 2012-05-18 | 2017-06-29 | Sumitomo Pharma Co., Ltd. | Carboxylic acid compounds |
US10280180B2 (en) | 2012-07-13 | 2019-05-07 | Janssen Sciences Ireland Uc | Macrocyclic purines for the treatment of viral infections |
JP6283033B2 (ja) | 2012-10-05 | 2018-02-21 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染症およびさらなる疾患の処置のためのアシルアミノピリミジン誘導体 |
CA2884478C (en) | 2012-10-10 | 2021-02-16 | Janssen Sciences Ireland Uc | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases |
CN105051018B (zh) | 2012-11-16 | 2019-09-20 | 爱尔兰詹森科学公司 | 用于治疗病毒性感染的杂环的经取代的2-氨基-喹唑啉衍生物 |
MY191389A (en) * | 2013-02-21 | 2022-06-22 | Janssen Sciences Ireland Uc | 2-aminopyrimidine derivatives for the treatment of viral infections |
WO2014154859A1 (en) | 2013-03-29 | 2014-10-02 | Janssen R&D Ireland | Macrocyclic deaza-purinones for the treatment of viral infections |
US10377738B2 (en) | 2013-05-24 | 2019-08-13 | Janssen Sciences Ireland Unlimited Company | Pyridone derivatives for the treatment of viral infections and further diseases |
EA202090258A3 (ru) | 2013-06-27 | 2020-07-31 | Янссен Сайенсиз Айрлэнд Юси | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний |
SG10201804306VA (en) | 2013-07-30 | 2018-06-28 | Janssen Sciences Ireland Uc | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS |
CA2994218A1 (en) | 2014-07-30 | 2016-02-04 | Cleveland Biolabs, Inc. | Flagellin compositons and uses |
MA40774A (fr) * | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
US10183056B2 (en) | 2014-10-16 | 2019-01-22 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
EP3360864B1 (en) | 2015-10-07 | 2021-04-28 | Sumitomo Dainippon Pharma Co., Ltd. | Pyrimidine compound |
SG11201811448RA (en) | 2016-07-01 | 2019-01-30 | Janssen Sciences Ireland Unlimited Co | Dihydropyranopyrimidines for the treatment of viral infections |
AU2017335205B2 (en) | 2016-09-29 | 2021-11-04 | Janssen Sciences Ireland Unlimited Company | Pyrimidine prodrugs for the treatment of viral infections and further diseases |
AU2017372722B2 (en) * | 2016-12-05 | 2021-09-09 | Apros Therapeutics, Inc. | Pyrimidine compounds containing acidic groups |
US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
JP7169968B2 (ja) | 2017-03-29 | 2022-11-11 | 住友ファーマ株式会社 | ワクチンアジュバント製剤 |
CA3085424A1 (en) | 2017-12-21 | 2019-06-27 | Sumitomo Dainippon Pharma Co., Ltd. | Combination drug including tlr7 agonist |
PE20211456A1 (es) * | 2018-02-28 | 2021-08-05 | Hoffmann La Roche | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado |
TW201945003A (zh) | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
EP3802519A1 (en) | 2018-06-04 | 2021-04-14 | Apros Therapeutics, Inc. | Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7 |
US20210353737A1 (en) | 2018-07-23 | 2021-11-18 | Japan As Represented By Director General Of National Institute Of Infectious Diseases | Composition containing influenza vaccine |
BR112021015577A8 (pt) | 2019-02-08 | 2021-10-05 | Research & Business Found Sungkyunkwan Univ | Complexo-colesterol agonista do receptor toll-like 7/8, composição de nanopartícula, composição adjuvante, composição de vacina, composição para regular uma função imunológica, composição farmacêutica e uso do complexo |
AU2021231160A1 (en) | 2020-03-02 | 2022-09-22 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
EP4194008A1 (en) | 2020-08-04 | 2023-06-14 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
US20230346924A1 (en) | 2020-08-04 | 2023-11-02 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
EP4194010A1 (en) | 2020-08-04 | 2023-06-14 | Progeneer Inc. | Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1375162A (es) | 1970-10-22 | 1974-11-27 | ||
GB1546937A (en) | 1976-07-29 | 1979-05-31 | Beecham Group Ltd | 2,4-diaminopyrimidine derivatives |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
IL78643A0 (en) | 1985-05-02 | 1986-08-31 | Wellcome Found | Purine derivatives,their preparation and pharmaceutical compositions containing them |
DE3603577A1 (de) | 1986-02-06 | 1987-08-13 | Joachim K Prof Dr Seydel | Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit |
JPH08165292A (ja) | 1993-10-07 | 1996-06-25 | Techno Res Kk | アデニン誘導体、その製造法及び用途 |
US5994361A (en) | 1994-06-22 | 1999-11-30 | Biochem Pharma | Substituted purinyl derivatives with immunomodulating activity |
US5736549A (en) | 1994-10-05 | 1998-04-07 | Chiroscience Limited | Hypoxanthine and guanine compounds |
ES2232871T3 (es) | 1996-07-03 | 2005-06-01 | Sumitomo Pharmaceuticals Company, Limited | Nuevos derivados de purina. |
EP1035123B1 (en) | 1997-11-28 | 2003-08-20 | Sumitomo Pharmaceuticals Company, Limited | Novel heterocyclic compounds |
TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
JP4189048B2 (ja) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
WO1999050249A2 (en) | 1998-04-01 | 1999-10-07 | Du Pont Pharmaceuticals Company | Pyrimidines and triazines as integrin antagonists |
WO2000012487A1 (fr) * | 1998-08-27 | 2000-03-09 | Sumitomo Pharmaceuticals Co., Ltd. | Derives de pyrimidine |
CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
AU6111000A (en) | 1999-07-22 | 2001-02-13 | Vertex Pharmaceuticals Incorporated | Inhibitors of viral helcase |
AU2001271867A1 (en) | 2000-07-07 | 2002-01-21 | Neotherapeutics, Inc. | Methods for treatment of conditions affected by activity of multidrug transporters |
US7157465B2 (en) | 2001-04-17 | 2007-01-02 | Dainippon Simitomo Pharma Co., Ltd. | Adenine derivatives |
CA2468011C (en) * | 2001-11-22 | 2012-04-10 | Japan Science And Technology Agency | Nonhuman model animal unresponsive to immunopotentiating synthetic compound |
US7115373B2 (en) | 2002-06-27 | 2006-10-03 | Genox Research, Inc. | Method of testing for atopic dermatitis by measuring expression of the NOR-1 gene |
NZ539064A (en) | 2002-09-27 | 2007-09-28 | Dainippon Sumitomo Pharma Co | Novel adenine compound and use thereof |
AU2004257149A1 (en) | 2003-06-20 | 2005-01-27 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (TLR) antagonists |
US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
DE602004026891D1 (de) | 2003-09-05 | 2010-06-10 | Anadys Pharmaceuticals Inc | Tlr7-liganden zur behandlung von hepatitis c |
CN1845745B (zh) * | 2003-09-05 | 2011-11-02 | 安那迪斯药品股份有限公司 | Tlr7配体及其前药在制备用于治疗丙型肝炎病毒感染的药物中的用途 |
RU2397171C2 (ru) | 2004-03-26 | 2010-08-20 | ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. | 9-замещенное производное 8-оксоаденина и лекарственное средство |
WO2005092892A1 (ja) | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | 8−オキソアデニン化合物 |
KR100700676B1 (ko) | 2005-06-24 | 2007-03-28 | (주) 비엔씨바이오팜 | 6―(4―치환된―아닐리노)피리미딘 유도체, 그 제조방법및 이를 포함하는 항바이러스용 약학적 조성물 |
US7759350B2 (en) | 2005-09-15 | 2010-07-20 | Orchid Research Laboratories Ltd. | Pyrimidine carboxamides |
EP1939202A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW COMPOUND OF ADENINE |
UY30444A1 (es) | 2006-06-30 | 2008-01-31 | Astrazeneca Ab | Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos. |
CL2007002231A1 (es) | 2006-08-02 | 2008-04-11 | Basf Ag | Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico. |
WO2008083465A1 (en) | 2007-01-08 | 2008-07-17 | University Health Network | Pyrimidine derivatives as anticancer agents |
AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
JPWO2008114819A1 (ja) | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
KR101225233B1 (ko) | 2007-09-05 | 2013-01-22 | 화이자 리미티드 | N4-(2,2-다이플루오로-4h-벤조〔1,4〕옥사진-3-온)-6-일〕-5-플루오로-n2-〔3-(메틸아미노카보닐메틸렌옥시)페닐〕2,4-피리미딘다이아민의 지나포에이트 염 |
PE20091236A1 (es) * | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
-
2010
- 2010-05-20 UY UY0001032648A patent/UY32648A/es not_active Application Discontinuation
- 2010-05-20 MX MX2011012337A patent/MX2011012337A/es not_active Application Discontinuation
- 2010-05-20 CN CN2010800338249A patent/CN102482233A/zh active Pending
- 2010-05-20 EP EP10721195.5A patent/EP2432768B1/en active Active
- 2010-05-20 JP JP2012511356A patent/JP5913093B2/ja active Active
- 2010-05-20 EA EA201101650A patent/EA201101650A1/ru unknown
- 2010-05-20 US US13/321,407 patent/US20120122867A1/en not_active Abandoned
- 2010-05-20 WO PCT/GB2010/050825 patent/WO2010133885A1/en active Application Filing
- 2010-05-20 SG SG2011078433A patent/SG175796A1/en unknown
- 2010-05-20 CA CA2760766A patent/CA2760766A1/en not_active Abandoned
- 2010-05-20 BR BRPI1010937A patent/BRPI1010937A2/pt not_active IP Right Cessation
- 2010-05-20 AU AU2010250923A patent/AU2010250923A1/en not_active Abandoned
- 2010-05-20 KR KR1020117030498A patent/KR20120030436A/ko not_active Application Discontinuation
- 2010-05-21 AR ARP100101776A patent/AR078045A1/es unknown
- 2010-05-21 TW TW099116416A patent/TW201100083A/zh unknown
-
2011
- 2011-11-10 IL IL216283A patent/IL216283A0/en unknown
- 2011-11-21 EC EC2011011470A patent/ECSP11011470A/es unknown
- 2011-11-21 CU CU20110212A patent/CU20110212A7/es unknown
- 2011-11-21 DO DO2011000361A patent/DOP2011000361A/es unknown
- 2011-11-21 CL CL2011002942A patent/CL2011002942A1/es unknown
- 2011-11-21 CR CR20110610A patent/CR20110610A/es unknown
- 2011-11-30 CO CO11165091A patent/CO6470845A2/es not_active Application Discontinuation
- 2011-12-20 ZA ZA2011/09384A patent/ZA201109384B/en unknown
-
2014
- 2014-08-26 US US14/469,515 patent/US9533978B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2432768B1 (en) | 2017-07-05 |
ZA201109384B (en) | 2012-09-26 |
CA2760766A1 (en) | 2010-11-25 |
US20150080396A1 (en) | 2015-03-19 |
WO2010133885A1 (en) | 2010-11-25 |
CL2011002942A1 (es) | 2012-04-13 |
CU20110212A7 (es) | 2012-03-15 |
CR20110610A (es) | 2012-01-09 |
US9533978B2 (en) | 2017-01-03 |
CO6470845A2 (es) | 2012-06-29 |
UY32648A (es) | 2010-12-31 |
SG175796A1 (en) | 2011-12-29 |
JP2012527443A (ja) | 2012-11-08 |
EP2432768A1 (en) | 2012-03-28 |
TW201100083A (en) | 2011-01-01 |
AR078045A1 (es) | 2011-10-12 |
AU2010250923A1 (en) | 2011-11-17 |
CN102482233A (zh) | 2012-05-30 |
US20120122867A1 (en) | 2012-05-17 |
EA201101650A1 (ru) | 2012-07-30 |
DOP2011000361A (es) | 2011-12-15 |
IL216283A0 (en) | 2012-01-31 |
JP5913093B2 (ja) | 2016-04-27 |
MX2011012337A (es) | 2011-12-08 |
BRPI1010937A2 (pt) | 2019-09-24 |
KR20120030436A (ko) | 2012-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP11011470A (es) | Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades | |
UY32611A (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
UY31183A1 (es) | Derivados de pirazinona y procesos para su preparación | |
SV2011003855A (es) | Heteroarilos sustituidos | |
CR20120264A (es) | Compuestos | |
CO6270324A2 (es) | Derivados de pirimidina para el tratamiento del asma epoc rinitis conjutivitis alergica dermatitis atopica cancer hepatitis b hepatitis c vih vph infecciones bacterianas y dermatosis | |
UY29002A1 (es) | Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia | |
UY30789A1 (es) | Derivados de adenina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
UY29795A1 (es) | Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones | |
UY31905A (es) | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
UY29803A1 (es) | Derivados de adeninas, composiciones farmacéuticas conteniéndolos, procedimientos de preparación y aplicaciones | |
BR112012029647A2 (pt) | novos derivados de pirimidinas | |
ECSP14013215A (es) | Compuestos novedosos | |
UY33078A (es) | Derivados de imidazoquinolina | |
UY33337A (es) | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS | |
UY32916A (es) | Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones | |
UY29767A1 (es) | Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones | |
UY29003A1 (es) | Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia | |
UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
UY30808A1 (es) | Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones | |
UY32673A (es) | Nuevas pirimidinas, composiciones farmaceuticas que las contienen, procedimientos de preparaciones y su aplicacion como medicamentos | |
UY29768A1 (es) | Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones | |
UY32744A (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 | |
CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
UY32623A (es) | Derivados bicíclicos para afecciones asociadas al receptor de andrógenos |